.cms-textAlign-left{text-align:left;}.cms-textAlign-center{text-align:center;}.cms-textAlign-right{text-align:right;}.cms-magazineStyles-smallCaps{font-variant:small-caps;}
The Centers for Medicare and Medicaid Services announced Tuesday that it would cover Biogen’s controversial Alzheimer’s treatment that was approved by the Food and Drug Administration in June — but only for those who enroll in ongoing clinical trials.
The proposed rule means that many older Americans with early-stage Alzheimer‘s disease will not have access to the drug, which targets amyloid build-ups in the brain thought to cause the disease.
FDA approved the drug on an accelerated pathway, which requires a fourth clinical trial to demonstrate
→ Continue reading at Politico
